obesity drug news today glp-1 october 23 2025 Alarming rise in weight loss overdoses New oral GLP-1 drugs could
Description
Association between plausible genetic factors and weight loss from GLP1-RA and bariatric surgery
Steady dose escalation to higher doses than for glycaemic control are indicated if: BMI is 30 kg/m 2 , or BMI 27 to 30 kg/m 2 , and for the range 2730 kg/m 2 if there is one weight-related comorbidity (hypertension, dyslipidaemia, cardiovascular disease, obstructive sleep apnoea, prediabetes or T2D
ArticlePubMed 17
The starting dose is 0.25 milligrams for 4 weeks before increasing the dosage to 0.5 milligrams
JAMA 2021;325:1414-25.PubMed 117
